棕榈酸帕利哌酮长效针剂对精神分裂症急性期及维持期的效果

Effect of paliperidone palmitate long-acting injection on schizophrenia patients in acute and maintenance stage

目的探讨精神分裂症患者使用棕榈酸帕利哌酮长效针剂的价值。方法本研究纳入80例精神分裂症患者(2020年1月~2021年4月),按随机数字表法分为对照组和观察组。对照组(n=40)采用利培酮治疗,观察组(n=40)采用棕榈酸帕利哌酮长效针剂治疗,统计比较两组临床疗效,不良反应,临床症状评分,心理社会功能。结果(1)临床疗效:观察组(95.00%)高于对照组(80.00%)(P<0.05)。(2)不良反应:观察组不良反应评分(1.24±1.05)低于对照组(2.87±1.41)(P<0.05)。(3)临床症状评分:治疗后3月,6月,12月,观察组阳性和阴性症状量表(PANSS)评分低于对照组(P<0.05)。(4)心理社会功能:治疗前,急性期个人和社会功能量表(PSP)评分对比无差异,维持期观察组PSP评分高于对照组(P<0.05)。结论棕榈酸帕利哌酮长效针剂在精神分裂症治疗中效果确切,可改善其临床症状及心理社会功能,亦可确保治疗安全性。

Objective To explore the value of palmitate piperazone long-term injection in the treatment of schizophrenia.Methods 80 patients with schizophrenia were included in the study(January 2020~April 2021).They were randomly divided into control group and observation group.The control group(n=40)were treated with risperidone and observation group(n=40)were treated with long-term injection of paliperidone palmitate.The clinical efficacy,adverse reactions,clinical symptom score and psychosocial function of the two groups were counted.Results(1)The clinical effect:the observation group(95.00%)was higher than that(80.00%)in control group(P<0.05).(2)Adverse reactions:The score of adverse reaction in observation group(1.24±1.05)lower than that(2.87±1.41)of control group(P<0.05).(3)Clinical symptom score:the observation group was positive,negative and Positive and negative symptom scale(PANSS)score was lower than that of the control group after 3 months,6 months and 12 months of treatment(P<0.05).(4)Psychosocial function:there was no difference in the score of PSP before treatment and acute stage,and the score of PSP in observation group was higher than that of control group in maintenance period(P<0.05).Conclusion Palmitate piperazone long-term injection has a definite effect in the treatment of schizophrenia,can improve their clinical symptoms and psychosocial function,and ensure the safety of treatment.